Ppargm1Btlr/Ppargm1Btlr
C57BL/6J-Ppargm1Btlr
|
decreased body weight |
J:265098
|
Ppargtm1.1Auw/Ppargtm1.1Auw
B6.Cg-Ppargtm1.1Auw
|
abnormal bone structure |
J:144344
|
|
abnormal cell differentiation |
J:144344
|
|
abnormal circadian temperature homeostasis |
J:144344
|
|
decreased body mass index |
J:144344
|
|
decreased body weight |
J:144344
|
|
decreased circulating cholesterol level |
J:144344
|
|
decreased circulating triglyceride level |
J:144344
|
|
decreased total fat pad weight |
J:144344
|
|
extended life span |
J:144344
|
|
normal
homeostasis/metabolism phenotype |
J:144344
|
|
hyperactivity |
J:144344
|
|
improved glucose tolerance |
J:144344
|
|
increased adipocyte glucose uptake |
J:144344
|
|
increased fluid intake |
J:144344
|
|
increased insulin sensitivity |
J:144344
|
Ppargtm1.1Auw/Ppargtm1.1Auw
either: 129 or C57BL/6J or (involves: 129 * C57BL/6J)
|
normal
adipose tissue phenotype |
J:86705
|
Ppargtm1.1Gonz/Ppargtm1.1Gonz
involves: 129X1/SvJ * FVB
|
cardiac hypertrophy |
J:112034
|
|
decreased heart rate |
J:112034
|
|
increased myocardial fiber size |
J:112034
|
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6
|
abnormal kidney morphology |
J:168799
|
|
abnormal macrophage activation involved in immune response |
J:168799
|
|
abnormal nephron morphology |
J:168799
|
|
abnormal peritoneal macrophage morphology |
J:168799
|
|
abnormal podocyte foot process morphology |
J:168799
|
|
abnormal renal glomerulus morphology |
J:168799
|
|
albuminuria |
J:168799
|
|
enlarged kidney |
J:168799
|
|
expanded mesangial matrix |
J:168799
|
|
fused podocyte foot processes |
J:168799
|
|
glomerulonephritis |
J:168799
|
|
impaired macrophage phagocytosis |
J:168799
|
|
increased anti-double stranded DNA antibody level |
J:168799
|
|
increased anti-nuclear antigen antibody level |
J:168799
|
|
increased anti-single stranded DNA antibody level |
J:168799
|
|
increased autoantibody level |
J:168799
|
|
increased circulating creatine level |
J:168799
|
|
increased IgG level |
J:168799
|
|
increased IgM level |
J:168799
|
|
increased kidney weight |
J:168799
|
|
increased mesangial cell number |
J:168799
|
|
increased renal glomerulus apoptosis |
J:168799
|
|
increased renal glomerulus basement membrane thickness |
J:168799
|
|
increased urine protein level |
J:168799
|
|
renal glomerulus hypertrophy |
J:168799
|
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Tg(Aqp2-cre)1Dek/0
involves: 129X1/SvJ * C57BL/6 * SJL
|
abnormal blood volume |
J:99873
|
|
abnormal body weight |
J:99873
|
|
abnormal circulating aldosterone level |
J:99873
|
|
abnormal hematocrit |
J:99873
|
|
abnormal physiological response to xenobiotic |
J:99873
|
|
abnormal renal sodium ion transport |
J:99873
|
|
abnormal urine sodium level |
J:99873
|
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Tg(Ins2-cre)25Mgn/0
involves: 129 * C57 * FVB
|
pancreatic islet hyperplasia |
J:89959
|
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Tg(Mx1-cre)1Cgn/?
involves: 129X1/SvJ * C57BL/6 * CBA * FVB/N
|
abnormal macrophage physiology |
J:75777
|
Ppargtm1.1Mgn/Ppargtm1.1Mgn
involves: 129S6/SvEvTac * C57BL/6J
|
no abnormal phenotype detected |
J:75120
|
Ppargtm1.1Mtz/Ppargtm1.1Mtz
involves: C57BL/6
|
abnormal placenta development |
J:89238
|
|
embryonic lethality during organogenesis, complete penetrance |
J:89238
|
Ppargtm1.2Auw/Ppargtm1.2Auw
B6.Cg-Ppargtm1.2Auw
|
premature death |
J:161746
|
Ppargtm1.2Mgn/Ppargtm1.2Mgn
involves: 129S6/SvEvTac * C57BL/6J
|
prenatal lethality, complete penetrance |
J:75120
|
Ppargtm1.2Mtz/Ppargtm1.2Mtz
Tg(Fabp4-cre/ERT2)1Ipc/0
involves: C57BL/6
|
abnormal adipose tissue physiology |
J:89238
|
|
abnormal brown fat cell morphology |
J:89238
|
|
abnormal white fat cell morphology |
J:89238
|
|
decreased brown adipose tissue amount |
J:89238
|
|
decreased epididymal fat pad weight |
J:89238
|
|
decreased percent body fat/body weight |
J:89238
|
|
increased brown fat cell lipid droplet size |
J:89238
|
Ppargtm1.2Mtz/Ppargtm1.2Mtz
Tg(Krt10-cre/ERT2)1Pcn/0
involves: C57BL/6 * SJL
|
abnormal keratinocyte morphology |
J:109090
|
|
abnormal skin morphology |
J:109090
|
Ppargtm1.2Mtz/Ppargtm1.2Mtz
Tg(KRT14-cre)1Ipc/0
involves: C57BL/6 * SJL
|
no abnormal phenotype detected |
J:109090
|
Ppargtm1Auw/Ppargtm1Auw
either: 129 or C57BL/6J or (involves: 129 * C57BL/6J)
|
abnormal brown adipose tissue morphology |
J:86705
|
|
abnormal circulating alanine transaminase level |
J:86705
|
|
abnormal glucose homeostasis |
J:86705
|
|
decreased body temperature |
J:86705
|
|
decreased body weight |
J:86705
|
|
decreased brown adipose tissue mass |
J:86705
|
|
decreased white adipose tissue mass |
J:86705
|
|
enlarged liver |
J:86705
|
|
hyperlipidemia |
J:86705
|
|
impaired glucose tolerance |
J:86705
|
|
increased circulating aspartate transaminase level |
J:86705
|
|
increased circulating free fatty acids level |
J:86705
|
|
increased circulating triglyceride level |
J:86705
|
|
increased liver triglyceride level |
J:86705
|
|
insulin resistance |
J:86705
|
|
lipodystrophy |
J:86705
|
|
macrovesicular hepatic steatosis |
J:86705
|
|
postnatal growth retardation |
J:86705
|
|
postnatal lethality, incomplete penetrance |
J:86705
|
Ppargtm1Avp/Pparg+
involves: 129S2/SvPas * C57BL/6
|
abnormal adipose tissue distribution |
J:116568
|
|
abnormal fat cell differentiation |
J:116568
|
|
abnormal lipid homeostasis |
J:116568
|
|
abnormal triglyceride level |
J:116568
|
|
decreased circulating adiponectin level |
J:116568
|
|
normal
growth/size/body region phenotype |
J:116568
|
|
hepatic steatosis |
J:116568
|
|
normal
homeostasis/metabolism phenotype |
J:116568
|
|
increased circulating triglyceride level |
J:116568
|
|
increased liver weight |
J:116568
|
Ppargtm1Avp/Ppargtm1Avp
involves: 129S2/SvPas * C57BL/6
|
preweaning lethality, complete penetrance |
J:116568
|
Ppargtm1b(KOMP)Wtsi/Pparg+
C57BL/6N-Ppargtm1b(KOMP)Wtsi/H
|
abnormal gait |
J:211773
|
|
decreased lean body mass |
J:211773
|
|
increased fasting circulating glucose level |
J:211773
|
|
increased total body fat amount |
J:211773
|
Ppargtm1b(KOMP)Wtsi/Ppargtm1b(KOMP)Wtsi
C57BL/6N-Ppargtm1b(KOMP)Wtsi/H
|
embryonic lethality prior to tooth bud stage |
J:211773
|
|
preweaning lethality, complete penetrance |
J:211773
|
Ppargtm1Gonz/Ppargtm1Gonz
Tg(MMTV-cre)1Mam/?
involves: 129X1/SvJ * FVB
|
abnormal mammary gland growth during pregnancy |
J:76553
|
|
decreased litter size |
J:76553
|
|
female infertility |
J:76553
|
|
reduced female fertility |
J:76553
|
Ppargtm1Gonz/Ppargtm1Gonz
Tg(MMTV-cre)4Mam/?
involves: 129X1/SvJ * FVB
|
normal
reproductive system phenotype |
J:76553
|
Ppargtm1Gonz/Ppargtm1Gonz
Tg(Wap-cre)11738Mam/?
involves: 129X1/SvJ * C57BL/6 * SJL
|
normal
reproductive system phenotype |
J:76553
|
Ppargtm1Laz/Ppargtm1Laz
involves: 129S6/SvEvTac * C57BL/6
|
abnormal glucose homeostasis |
J:135904
|
|
decreased circulating free fatty acids level |
J:135904
|
|
decreased circulating leptin level |
J:135904
|
|
decreased circulating triglyceride level |
J:135904
|
|
decreased fat cell size |
J:135904
|
|
improved glucose tolerance |
J:135904
|
|
increased circulating adiponectin level |
J:135904
|
|
increased insulin sensitivity |
J:135904
|
Ppargtm1Lja/Pparg+
involves: 129S1/Sv * 129X1/SvJ
|
abnormal brown fat cell morphology |
J:98786
|
|
abnormal epididymal fat pad morphology |
J:98786
|
|
decreased body fat mass |
J:98786
|
|
decreased body weight |
J:98786
|
|
decreased circulating adiponectin level |
J:98786
|
|
decreased muscle cell glucose uptake |
J:98786
|
|
decreased white fat cell size |
J:98786
|
|
hypertension |
J:98786
|
|
increased circulating free fatty acids level |
J:98786
|
|
increased circulating insulin level |
J:98786
|
|
increased liver triglyceride level |
J:98786
|
|
insulin resistance |
J:98786
|
|
lipodystrophy |
J:98786
|
|
macrovesicular hepatic steatosis |
J:98786
|
|
microvesicular hepatic steatosis |
J:98786
|
Ppargtm1Lja/Ppargtm1Lja
involves: 129S1/Sv * 129X1/SvJ
|
decreased embryo size |
J:98786
|
|
embryonic lethality, complete penetrance |
J:98786
|
Ppargtm1Mae/Pparg+
involves: 129S6/SvEvTac * C57BL/6
|
abnormal adipose tissue distribution |
J:91362
|
|
abnormal endocrine pancreas morphology |
J:91362
|
|
abnormal fat cell morphology |
J:91362
|
|
abnormal gonadal fat pad morphology |
J:91362
|
|
abnormal inguinal fat pad morphology |
J:91362
|
|
hypertension |
J:91362
|
|
improved glucose tolerance |
J:91362
|
Ppargtm1Mae/Ppargtm1Mae
involves: 129S6/SvEvTac * C57BL/6
|
prenatal lethality, complete penetrance |
J:91362
|
Ppargtm1Rev/Pparg+
involves: 129S4/SvJae * C57BL/6J
|
abnormal glucose homeostasis |
J:60354
|
|
increased insulin sensitivity |
J:60354
|
Ppargtm1Rev/Ppargtm1Rev
involves: 129S4/SvJae
|
abnormal chorionic plate morphology |
J:58223
|
|
abnormal fetal cardiomyocyte mitochondrial morphology |
J:58223
|
|
abnormal fetal cardiomyocyte morphology |
J:58223
|
|
abnormal myocardial trabeculae morphology |
J:58223
|
|
abnormal placenta hemotrichorial membrane morphology |
J:58223
|
|
abnormal placenta labyrinth morphology |
J:58223
|
|
abnormal placenta morphology |
J:58223
|
|
abnormal placental labyrinth vasculature morphology |
J:58223
|
|
abnormal trophoblast giant cell morphology |
J:58223
|
|
abnormal trophoblast layer morphology |
J:58223
|
|
embryonic lethality during organogenesis, complete penetrance |
J:58223
|
|
thin interventricular septum |
J:58223
|
|
thin myocardium |
J:58223
|
|
thin ventricle myocardium compact layer |
J:58223
|
|
thin ventricular wall |
J:58223
|
Ppargtm1Rev/Ppargtm2Mae
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J
|
increased systemic arterial blood pressure |
J:154767
|
Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA
|
abnormal bone marrow development |
J:89250
|
|
abnormal bone marrow morphology |
J:89250
|
|
abnormal bone ossification |
J:89250
|
|
abnormal cell differentiation |
J:58222
|
|
abnormal fat cell morphology |
J:58222,
J:89250
|
|
abnormal osteoblast differentiation |
J:89250
|
|
abnormal response to injury |
J:103209
|
|
abnormal retina vasculature morphology |
J:116269
|
|
decreased brown adipose tissue amount |
J:58222
|
|
decreased circulating insulin level |
J:58222
|
|
decreased food intake |
J:58222
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:58222
|
|
decreased susceptibility to diet-induced obesity |
J:58222
|
|
decreased total body fat amount |
J:58222
|
|
increased body temperature |
J:58222
|
|
increased circulating leptin level |
J:58222
|
|
increased incidence of tumors by chemical induction |
J:98823
|
|
increased insulin sensitivity |
J:58222
|
|
increased osteoblast cell number |
J:89250
|
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:98823
|
|
increased trabecular bone mass |
J:89250
|
|
leukostasis |
J:116269
|
|
normal
skeleton phenotype |
J:89250
|
Ppargtm1Tka/Pparg+
involves: C57BL/6 * CBA * ICR
|
abnormal B cell physiology |
J:58222
|
|
abnormal humoral immune response |
J:58222
|
|
abnormal response to injury |
J:68579
|
|
normal
immune system phenotype |
J:58222
|
|
increased B cell proliferation |
J:58222
|
|
increased IgG level |
J:58222
|
|
increased IgM level |
J:58222
|
|
increased interferon-gamma secretion |
J:58222
|
|
increased interleukin-2 secretion |
J:58222
|
|
increased susceptibility to induced arthritis |
J:58222
|
Ppargtm1Tka/Ppargtm1Tka
involves: C57BL/6 * CBA
|
abnormal cell differentiation |
J:58222,
J:89250
|
|
abnormal heart development |
J:58222
|
|
abnormal placenta labyrinth morphology |
J:58222
|
|
abnormal placental labyrinth vasculature morphology |
J:58222
|
|
embryonic growth retardation |
J:58222
|
|
embryonic lethality during organogenesis, complete penetrance |
J:58222
|
|
placental labyrinth hypoplasia |
J:58222
|
|
thin myocardium |
J:58222
|
Ppargtm1Uls/Pparg+
involves: 129S2/SvPas * C57BL/6
|
decreased total body fat amount |
J:92826
|
|
postnatal growth retardation |
J:92826
|
Ppargtm1Uls/Ppargtm1Uls
involves: 129S2/SvPas * C57BL/6
|
prenatal lethality, complete penetrance |
J:92826
|
Ppargtm1Wwah/Pparg+
Not Specified
|
normal
immune system phenotype |
J:71272
|
Ppargtm1Wwah/Ppargtm1Wwah
Not Specified
|
prenatal lethality |
J:71272
|
Ppargtm1Yec/Ppargtm1Yec
involves: 129S4/SvJae * C57BL/6
|
abnormal brown adipose tissue morphology |
J:91479
|
|
abnormal white adipose tissue morphology |
J:91479
|
|
abnormal white adipose tissue physiology |
J:91479
|
|
decreased body weight |
J:91479
|
|
decreased brown fat cell lipid droplet size |
J:91479
|
|
decreased brown fat lipid droplet number |
J:91479
|
|
decreased circulating adiponectin level |
J:91479
|
|
decreased circulating leptin level |
J:91479
|
|
decreased gonadal fat pad weight |
J:91479
|
|
decreased inguinal fat pad weight |
J:91479
|
|
decreased retroperitoneal fat pad weight |
J:91479
|
|
decreased white adipose tissue amount |
J:91479
|
|
decreased white fat cell number |
J:91479
|
|
decreased white fat cell size |
J:91479
|
|
insulin resistance |
J:91479
|
|
normal
liver/biliary system phenotype |
J:91479
|
Ppargtm2(tTA)Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
|
abnormal brown adipose tissue morphology |
J:125992
|
|
abnormal hepatocyte morphology |
J:125992
|
|
abnormal white adipose tissue morphology |
J:125992
|
|
abnormal white fat cell morphology |
J:125992
|
|
abnormal white fat cell size |
J:125992
|
|
absent subcutaneous adipose tissue |
J:125992
|
|
normal
adipose tissue phenotype |
J:125992
|
|
decreased gonadal fat pad weight |
J:125992
|
|
enlarged liver |
J:125992
|
|
normal
homeostasis/metabolism phenotype |
J:125992
|
|
hyperglycemia |
J:125992
|
|
impaired glucose tolerance |
J:125992
|
|
increased brown fat cell size |
J:125992
|
|
increased circulating cholesterol level |
J:125992
|
|
increased circulating free fatty acids level |
J:125992
|
|
increased circulating insulin level |
J:125992
|
|
increased circulating triglyceride level |
J:125992
|
|
increased interscapular fat pad weight |
J:125992
|
|
insulin resistance |
J:125992
|
|
pancreas hyperplasia |
J:125992
|
|
pancreatic islet hyperplasia |
J:125992
|
|
reduced fertility |
J:125992
|
Ppargtm2Avp/Ppargtm2Avp
involves: 129/Sv * C57BL/6
|
abnormal pancreatic islet morphology |
J:121534
|
|
decreased circulating adiponectin level |
J:121534
|
Ppargtm2Avp/Ppargtm2Avp
Not Specified
|
abnormal adipose tissue distribution |
J:121693
|
|
abnormal glucose homeostasis |
J:121693
|
|
abnormal white adipose tissue physiology |
J:121693
|
|
decreased circulating adiponectin level |
J:121693
|
|
decreased total body fat amount |
J:121693
|
|
impaired glucose tolerance |
J:121693
|
|
increased circulating glucose level |
J:121693
|
|
increased circulating leptin level |
J:121693
|
|
increased fat cell size |
J:121693
|
|
normal
reproductive system phenotype |
J:121693
|
Ppargtm2Rev/Ppargtm2Rev
Tg(Camk2a-cre)62Jzt/?
B6.Cg-Ppargtm2Rev Tg(Camk2a-cre)62Jzt
|
abnormal neuron physiology |
J:148757
|
|
normal
behavior/neurological phenotype |
J:148757
|
|
brain ischemia |
J:148757
|
|
normal
growth/size/body region phenotype |
J:148757
|
|
normal
homeostasis/metabolism phenotype |
J:148757
|
|
normal
nervous system phenotype |
J:148757
|
Ppargtm2Rev/Ppargtm2Rev
Tg(Cd4-cre)1Cwi/?
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
abnormal T-helper 17 cell differentiation |
J:153358
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:153358
|
Ppargtm2Rev/Ppargtm2Rev
Tg(Fabp4-cre)1Rev/0
involves: 129S4/SvJae * C57BL/6
|
abnormal brown adipose tissue morphology |
J:88210
|
|
abnormal brown fat cell size |
J:88210
|
|
abnormal white adipose tissue amount |
J:88210
|
|
decreased brown adipose tissue amount |
J:88210
|
|
decreased brown fat cell number |
J:88210
|
|
decreased interscapular fat pad weight |
J:88210
|
|
enlarged liver |
J:88210
|
|
hepatic steatosis |
J:88210
|
|
increased brown fat cell size |
J:88210
|
|
increased circulating insulin level |
J:88210
|
|
increased white fat cell size |
J:88210
|
|
insulin resistance |
J:88210
|
|
slow postnatal weight gain |
J:88210
|
Ppargtm2Rev/Ppargtm2Rev
Tg(Krt1-15-cre/PGR*)22Cot/?
involves: 129S4/SvJae * C57BL/6 * SJL
|
abnormal coat appearance |
J:150977
|
|
abnormal hair follicle morphology |
J:150977
|
|
abnormal hair follicle ostium morphology |
J:150977
|
|
abnormal skin adnexa morphology |
J:150977
|
|
abnormal skin appearance |
J:150977
|
|
abnormal skin morphology |
J:150977
|
|
abnormal skin sebaceous gland morphology |
J:150977
|
|
excessive scratching |
J:150977
|
|
flaky skin |
J:150977
|
|
hyperkeratosis |
J:150977
|
|
matted coat |
J:150977
|
|
progressive hair loss |
J:150977
|
|
reddish skin |
J:150977
|
|
sebaceous gland atrophy |
J:150977
|
|
skin fibrosis |
J:150977
|
|
skin inflammation |
J:150977
|
Ppargtm2Rev/Ppargtm2Rev
Tg(Lhb-cre)1Sac/?
involves: 129S4/SvJae * C57BL/6 * SJL
|
abnormal diestrus |
J:170272
|
|
decreased circulating follicle stimulating hormone level |
J:170272
|
|
decreased litter size |
J:170272
|
|
increased luteinizing hormone level |
J:170272
|
|
normal
reproductive system phenotype |
J:170272
|
Ppargtm2Rev/Ppargtm2Rev
Tg(Tagln-cre)1Her/?
involves: 129S4/SvJae * C57BL/6 * SJL
|
abnormal pulmonary artery morphology |
J:136168
|
|
heart right ventricle hypertrophy |
J:136168
|
|
increased right ventricle systolic pressure |
J:136168
|
Ppargtm2Rev/Ppargtm2Rev
Tg(Tek-cre)1Ywa/?
involves: 129S4/SvJae * C57BL/6 * SJL
|
abnormal bone marrow cavity morphology |
J:130475
|
|
abnormal bone marrow cell morphology/development |
J:130475
|
|
abnormal bone structure |
J:130475
|
|
abnormal bone trabecula morphology |
J:130475,
J:160910
|
|
abnormal hair cycle |
J:123403
|
|
abnormal hair cycle anagen phase |
J:123403
|
|
abnormal hair follicle morphology |
J:123403
|
|
abnormal hair shedding |
J:123403
|
|
abnormal mammary gland alveolus morphology |
J:123403
|
|
abnormal osteoclast differentiation |
J:160910
|
|
abnormal osteoclast morphology |
J:130475
|
|
abnormal pulmonary artery morphology |
J:155909
|
|
abnormal skin adnexa morphology |
J:123403
|
|
abnormal spleen morphology |
J:130475
|
|
abnormal splenocyte morphology |
J:130475
|
|
abnormal trabecular bone morphology |
J:130475
|
|
decreased bone marrow cell number |
J:130475
|
|
decreased osteoclast cell number |
J:130475
|
|
enlarged spleen |
J:130475
|
|
extramedullary hematopoiesis |
J:130475
|
|
heart right ventricle hypertrophy |
J:155909
|
|
normal
hematopoietic system phenotype |
J:130475
|
|
increased bone mineral density |
J:130475
|
|
increased bone trabecula number |
J:130475
|
|
increased bone volume |
J:130475
|
|
increased right ventricle systolic pressure |
J:155909
|
|
increased splenocyte number |
J:130475
|
|
increased trabecular bone thickness |
J:130475
|
|
increased trabecular bone volume |
J:130475
|
|
increased triglyceride level |
J:155909
|
|
pale liver |
J:123403
|
|
postnatal growth retardation |
J:123403
|
|
premature hair loss |
J:123403
|
|
skin inflammation |
J:123403
|
Ppargtm2Rev/Ppargtm2Rev
Tg(Tek-cre)12Flv/?
B6.Cg-Ppargtm2Rev Tg(Tek-cre)12Flv
|
abnormal vascular endothelial cell physiology |
J:154216
|
|
abnormal vasodilation |
J:154216
|
|
decreased body weight |
J:154216
|
|
decreased hematocrit |
J:154216
|
|
enlarged spleen |
J:154216
|
|
impaired muscle relaxation |
J:154216
|
|
increased mean systemic arterial blood pressure |
J:154216
|
Ppargtm2Rev/Ppargtm2Rev
Tg(Ucp1-cre)1Evdr/0
involves: 129S4/SvJae * FVB
|
abnormal amino acid metabolism |
J:278806
|
|
abnormal interscapular fat pad morphology |
J:278806
|
Ppargtm3(tTA)Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
|
abnormal brown adipose tissue morphology |
J:125992
|
|
abnormal brown fat cell morphology |
J:125992
|
|
decreased gonadal fat pad weight |
J:125992
|
|
decreased subcutaneous adipose tissue amount |
J:125992
|
|
enlarged liver |
J:125992
|
|
increased brown fat cell size |
J:125992
|
|
increased circulating insulin level |
J:125992
|
|
increased circulating triglyceride level |
J:125992
|
Excel File
Analysis Tools